2.Drug-induced bile duct injury: progress and challenges.
Chinese Journal of Hepatology 2023;31(4):339-344
Drug-induced bile duct injury is a specific kind of drug-induced liver injury that has two main pathological types, namely ductopenia, or vanishing bile duct syndrome, and secondary sclerosing cholangitis. However, in recent years, the reports of new drugs that cause bile duct injury have been constantly increasing, and these drugs have different clinicopathological features and a novel pathogenesis. Therefore, this paper summarizes and analyzes the progress and challenges in the etiology, pathogenesis, diagnosis and treatment, and other aspects of drug-induced bile duct injury.
Humans
;
Cholestasis/chemically induced*
;
Cholangitis, Sclerosing/diagnosis*
;
Chemical and Drug Induced Liver Injury/pathology*
;
Bile Ducts/pathology*
3.Significance of histological assessment in drug-induced liver injury.
Chinese Journal of Hepatology 2023;31(4):349-354
Liver histological assessment is of great clinical significance for the diagnosis, classification, and prognosis prediction of drug-induced liver injury (DILI). Liver histological evaluation can effectively supplement RUCAM. The clinical phenotypes of DILI are complex and diverse, including acute, chronic and severe hepatic injury. DILI has multiple insult-targets, including hepatocytes, cholangiocytes, and vascular endothelial cells and others. The pathological damage patterns are similar to many types of non-DILI liver diseases, therefore making differential diagnosis difficult. New anti-tumor drugs such as immune checkpoints inhibitors and targeted therapy are widely used in clinical antineoplastic practice, thus the growing incidence of related liver injury occurs. Liver histological examination can effectively assess the pathological phenotypes and severity of DILI, so as to guide treatment. In uncommon conditions such as special types of DILI (such as hepatic vascular disease), DILI with other competitive etiology overlapping, chronic DILI, and DILI induced liver failure, liver histological assessment can provide strong support for identifying the cause, rational treatment, and prognosis. Currently, the histological evaluation system for drug-induced liver injury seems to be a lack of consensus, and the diagnosis of DILI is short of highly specific and sensitive serological markers. All in all, liver histological assessment plays a crucial role in the diagnosis and differential diagnosis of DILI.
Humans
;
Endothelial Cells
;
Chemical and Drug Induced Liver Injury/pathology*
;
Liver/pathology*
;
Hepatocytes
;
Phenotype
;
Antineoplastic Agents/pharmacology*
4.Mechanisms of drug-induced liver injury.
Chinese Journal of Hepatology 2012;20(3):163-166
7.Herb-Induced Liver Injury: A Global Concern.
Chinese journal of integrative medicine 2018;24(9):643-644
Chinese medicine and herb medicine though used to treat liver diseases are an important cause of liver injury. Many phytochemicals have the potential to injure the liver, some in a dose-related fashion and more often in an idiosyncratic fashion, meaning occurrence is uncommon to rare in the population using these treatments. As is the case with pharmaceuticals, the phytochemicals are usually tolerated despite either no or mild transient subclinical injury but rarely in some susceptible patients cause moderate to severe liver injury which is likely mediated by the adaptive immune system.
Animals
;
Chemical and Drug Induced Liver Injury
;
pathology
;
Drugs, Chinese Herbal
;
adverse effects
;
Humans
;
Practice Guidelines as Topic
9.Liver fibrosis inhibits lethal injury through D-galactosamine/lipopolysaccharide-induced necroptosis.
Lu LI ; Li BAI ; Su Jun ZHENG ; Yu CHEN ; Zhong Ping DUAN
Chinese Journal of Hepatology 2022;30(4):413-418
Objective: To explore the new mechanism of liver fibrosis through D-galactosamine/lipopolysaccharide (D-GalN/LPS)-induced necroptosis as an entry point to inhibit lethal injury. Methods: The carbon tetrachloride (CCl4)-induced mouse model of liver fibrosis was established. At 6 weeks of fibrosis, the mice were challenged with a lethal dose of D-GalN/LPS, and the normal mice treated with the same treatment were used as the control. The experiment was divided into four groups: control group (Control), acute injury group (D-GalN/LPS), liver fibrosis group (Fib), and liver fibrosis + acute challenge group (Fib + D-GalN/LPS). Quantitative PCR and immunofluorescence were used to analyze the expression of necroptosis key signal molecules RIPK1, RIPK3, MLKL and/or P-MLKL in each group. Normal mice were treated with inhibitors targeting key signaling molecules of necroptosis, and then given an acute challenge. The inhibitory effect of D-GalN/LPS-induced-necroptosis on acute liver injury was evaluated according to the changes in transaminase levels and liver histology. Liver fibrosis spontaneous ablation model was established, and then acute challenge was given. Necroptosis key signal molecules expression was analyzed in liver tissue of mice in each group and compared by immunohistochemistry. The differences between groups were compared with t-test or analysis of variance. Results: Quantitative PCR and immunofluorescence assays result showed that D-GalN/LPS-induced significant upregulation of RIPK1, RIPK3, MLKL and/or P-MLKL. Necroptosis key signal molecules inhibition had significantly reduced D-GalN/LPS-induced liver injury, as manifested by markedly reduced serum ALT and AST levels with improvement in liver histology. Necroptosis signaling molecules expression was significantly inhibited in fibrotic livers even under acute challenge conditions. Additionally, liver fibrosis with gradual attenuation of fibrotic ablation had inhibited D-GalN/LPS-induced necroptosis. Conclusion: Liver fibrosis may protect mice from acute lethal challenge injury by inhibiting D-GalN/LPS-induced necroptosis.
Animals
;
Chemical and Drug Induced Liver Injury/pathology*
;
Galactosamine/adverse effects*
;
Lipopolysaccharides/adverse effects*
;
Liver/pathology*
;
Liver Cirrhosis/pathology*
;
Liver Failure, Acute/chemically induced*
;
Mice
;
Necroptosis
10.Advances in clinical diagnosis and treatment of drug-induced liver injury in children.
Xiao Rong PENG ; Yu Nan CHANG ; Tao QIN ; Ting Ting SHANG ; Hong Mei XU
Chinese Journal of Hepatology 2023;31(4):440-444
Drug-induced liver injury (DILI) is one of the most common adverse drug reactions that may seriously threaten the health of children and is receiving increasing clinical attention day by day. There is still no independent diagnosis and treatment guideline for DILI in children, but its clinical features are not completely similar to those in adults. This article reviews the epidemiology, clinical features, diagnosis, and treatment progress in order to provide a reference for the management of DILI in children.
Child
;
Humans
;
Chemical and Drug Induced Liver Injury/therapy*
;
Drug-Related Side Effects and Adverse Reactions
;
Liver/pathology*
;
Risk Factors